ahlam1399
07-15-2016, 06:09 AM
LONDON :British medical charity MRC Tech**logy has pocketed $150 million by selling part of its
royalty interest in Merck & Co´s successful cancer drug Keytruda, allowing it to plough fresh funds into new research.
The charity said on Friday that a private equity fund managed by DRI Capital had acquired a portion of its royalty entitlement on the worldwide sales of the medicine.
Keytruda is one of a promising class of new treatments that stimulate the body´s immune system to fight cancer.
It is an antibody-based medicine and was "humanised" by scientists at MRC Tech**logy.
http://feeds.feedburner.com/~r/com/YEor/~4/fEzaa6aM-B4
أكثر... (http://feedproxy.google.com/~r/com/YEor/~3/fEzaa6aM-B4/135074-UK-charity-pockets-150-mln-from-Merck-cancer-immu**therapy-drug)
royalty interest in Merck & Co´s successful cancer drug Keytruda, allowing it to plough fresh funds into new research.
The charity said on Friday that a private equity fund managed by DRI Capital had acquired a portion of its royalty entitlement on the worldwide sales of the medicine.
Keytruda is one of a promising class of new treatments that stimulate the body´s immune system to fight cancer.
It is an antibody-based medicine and was "humanised" by scientists at MRC Tech**logy.
http://feeds.feedburner.com/~r/com/YEor/~4/fEzaa6aM-B4
أكثر... (http://feedproxy.google.com/~r/com/YEor/~3/fEzaa6aM-B4/135074-UK-charity-pockets-150-mln-from-Merck-cancer-immu**therapy-drug)